Drug General Information
Drug ID
D06MAJ
Former ID
DAP001403
Drug Name
Mizolastine
Synonyms
Mistalin; Mistamine; Mizolastina; Mizolastinum; Mizolen; Mizollen; Zolim; Zolistam; Zolistan; Allphar brand of mizolastine; Galderma brand of mizolastine; Mizolastine [INN]; Novag brand of mizolastine; Sanofi Synthelabo brand of mizolastine; Schwarz brand of mizolastine; MKC-431; Mizolastina [INN-Spanish]; Mizolastinum [INN-Latin]; Mizollen (TN); SL 85.0324; Mizolastine (JAN/INN); SL-85.0324; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
Drug Type
Small molecular drug
Indication Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] Approved [535216]
Therapeutic Class
Antiallergic Agents
Structure
Download
2D MOL

3D MOL

Formula
C24H25FN6O
Canonical SMILES
CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(<br />=O)N5
InChI
1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
InChIKey
PVLJETXTTWAYEW-UHFFFAOYSA-N
CAS Number
CAS 108612-45-9
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
R06AX25
SuperDrug CAS ID
cas=108612459
Target and Pathway
Target(s) Histamine H1 receptor Target Info Antagonist [536717]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Inflammatory mediator regulation of TRP channels
PANTHER Pathway Histamine H1 receptor mediated signaling pathway
Reactome Histamine receptors
G alpha (q) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
IL-4 Signaling Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 535216Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):299-319.
Ref 536717Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.